Anlotinib for Recurrent or Metastatic Primary Malignant Bone Tumor: A Multicenter, Single-Arm Trial

OBJECTIVE: Anlotinib, a novel multitarget kinase inhibitor of VEGFR, FGFR, PDGFR and c-Kit, has proven to be effective and safe for refractory soft tissue sarcoma patients, but has not been examined in recurrent or metastatic primary malignant bone tumors in a clinical trial setting. METHODS: This i...

Descripción completa

Detalles Bibliográficos
Autores principales: Tang, Lina, Niu, Xiaohui, Wang, Zhen, Cai, Qiqing, Tu, Chongqi, Fan, Zhengfu, Yao, Yang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9177947/
https://www.ncbi.nlm.nih.gov/pubmed/35692789
http://dx.doi.org/10.3389/fonc.2022.811687

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9177947/
https://www.ncbi.nlm.nih.gov/pubmed/35692789
http://dx.doi.org/10.3389/fonc.2022.811687

Ejemplares similares